Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?
2026-07-18 13:15
•Reuben Gregg Brewer •The Motley Fool
•••• • Axe Capital view
Pfizer’s Dividend at Risk as Patent Cliff Looms
Pfizer’s generous dividend yield hides serious sustainability concerns amid patent expiries and a thin drug pipeline.
Pfizer is handing out a juicy 7% dividend, which on the surface looks attractive. But dig a little deeper, and you see the company is paying out more than it earns, a sign dividends here may not last. The problem? Several high-selling drugs lose patent protection in 2027 and 2028, giving generic competitors a clear path. Pfizer’s R&D pipeline isn’t strong enough to fill this gap, especially after recent stumbles like the GLP-1 candidate failure. Cash reserves and borrowing can help patch things over in the short term, but sustaining a payout ratio over 130% is not a long-term plan. For South African investors eyeing offshore dividends or considering Pfizer exposure through USD/ZAR moves, caution is warranted. If the company cuts dividends or earnings slide, global risk sentiment could influence the rand negatively. this is just my opinion and not financial advice
I would avoid buying Pfizer now, preferring to wait until the company proves new drugs can offset patent losses. For rand investors, keep an eye on USD/ZAR volatility linked to these pharma earnings shocks.
- PFE
- USD/ZAR
- Patent expiries undermine earnings
- R&D pipeline fails to deliver new blockbusters
- Dividend cut impacts share price and rand sentiment
7/10
Pfizer's attractive 7% dividend yield masks significant risks as the company faces a patent cliff with major drugs losing protection in 2027-2028. With a dividend payout ratio over 130% and limited new drug candidates in the pipeline, investors are concerned about the sustainability of the dividend. However, the company has cash reserves and debt options to maintain payments, and management has prioritized dividend preservation.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Reuben Gregg Brewer
Categories: Rates, Equities, Capital Returns, Healthcare
Tickers: PFE
Sentiment: Negative - Pfizer faces significant headwinds from upcoming patent expirations of major drugs (Ibrance in 2027, Eliquis and Vyndaqel in 2028) with insufficient new drug candidates to replace them. The dividend payout ratio exceeds 130%, raising sustainability concerns. Recent setback with GLP-1 drug candidate adds to concerns about R&D pipeline effectiveness.
Keywords: patent cliff, dividend sustainability, pharmaceutical R&D, drug patent expiration, dividend yield, cash flow, generic competition
Insights:
- PFE: Negative: Pfizer faces significant headwinds from upcoming patent expirations of major drugs (Ibrance in 2027, Eliquis and Vyndaqel in 2028) with insufficient new drug candidates to replace them. The dividend payout ratio exceeds 130%, raising sustainability concerns. Recent setback with GLP-1 drug candidate adds to concerns about R&D pipeline effectiveness.